Breakthroughs in Personalized Medicine: Neoantigen Identification and TCR-T Therapy Development

Researchers from the State Key Laboratory of Molecular Oncology have made significant strides in personalized medicine, focusing on the identification and targeting of neoantigens in solid tumors. This promising approach utilizes T cell receptor (TCR-T) cells, engineered to selectively kill tumor cells while minimizing damage to healthy cells. The study, published in the Journal of the National Cancer Center, explores the characteristics and advantages of neoantigens, strategies for identifying and validating them, and the therapeutic effectiveness of TCR-T therapy.

Key Takeaways:

• The research emphasizes the importance of neoantigens in solid tumor therapy, as they offer superior specificity and are uniquely expressed on tumor cells due to genomic alterations.
• Previous studies have focused on tumor-associated antigens, which exhibit expression in both tumor and normal cells, resulting in off-target risk.
• The study highlights the need to identify and target neoantigens, which are valuable therapeutic targets due to their frequent occurrence and notable role in tumorigenesis and tumor progression.
• TCR-T cells have become recognized as a promising tumor cell therapy, with several studies and clinical tests demonstrating their potential as a novel therapy.
• The research also discusses significant and representative studies involving TCR-T and other immunotherapies that target neoantigens to assess the therapeutic effectiveness of TCR-T therapy.
• Challenges and complexities inherent in TCR-T therapy, such as off-target risk and heterogeneity of different patients, are also addressed, with potential solutions proposed.

Statistics:

• 5-5(5):429-440 is the issue and page numbers for the research published in the Journal of the National Cancer Center.
• 2025 is the year in which the research was conducted.
• 941 is the page number for the news report in Cancer Weekly.
• The research involves collaboration between former and current researchers from the State Key Laboratory of Molecular Oncology, with authors Yahui Zhao, Xinyao Zheng, and Zhihua Liu.

Sources:

• Journal of the National Cancer Center
• Cancer Weekly
• State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
• NewsRx LLC
• National Cancer Center
• Chinese Academy of Medical Sciences